67 related articles for article (PubMed ID: 25043278)
1. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China.
Kang G; Tang F; Wang Z; Hu R; Yu J; Gao J
Hum Vaccin Immunother; 2021 Aug; 17(8):2568-2574. PubMed ID: 33780310
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.
Leroux-Roels I; Leroux-Roels G; Shukarev G; Schuitemaker H; Cahill C; de Rooij R; Struijs M; van Zeeburg H; Jacquet JM
Hum Vaccin Immunother; 2021 May; 17(5):1366-1373. PubMed ID: 33175637
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.
Xu J; Liu Y; Qiu W; Li W; Hu X; Li X; Fan Q; Tang W; Wang Y; Wang Q; Yao N
BMC Infect Dis; 2024 May; 24(1):535. PubMed ID: 38807038
[TBL] [Abstract][Full Text] [Related]
6. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
Sun G; Wang G; Zhong H
Inflammopharmacology; 2024 Apr; 32(2):1025-1038. PubMed ID: 38308795
[TBL] [Abstract][Full Text] [Related]
7. Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months.
Feng G; Shao M; Wang J; Huang L; Tan J; Jiang Z; You W; Li Y; Yang Y; Li J; Wang Y
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400106
[TBL] [Abstract][Full Text] [Related]
8. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.
Eggers M; Terletskaia-Ladwig E; Rabenau HF; Doerr HW; Diedrich S; Enders G; Enders M
BMC Infect Dis; 2010 Dec; 10():347. PubMed ID: 21143885
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.
Chen S; Ying Z; Liu Y; Li Y; Yu Y; Huang M; Huang Z; Ou Z; Liao Y; Zhang Y; Liu G; Zhao W; Fu R; Shou Q; Zheng M; Liao X; Tu Y; Stek J; Hartzel J; Li C; Zhang J
Hum Vaccin Immunother; 2024 Dec; 20(1):2324538. PubMed ID: 38509699
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase Ⅳ clinical trial.
Yin Q; Zheng Y; Ying Z; Li J; Jiang Y; Bao W; Dou Y; Pu Y; Lei J; Yang H; Jiang R; Deng Y; Zhao Z; Pu J; Yang J; Li Y; Xu M; Cai W; Che Y; Shi L
Vaccine; 2024 Mar; 42(8):1973-1979. PubMed ID: 38388236
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial.
Wang Y; Xu Q; Jeyaseelan V; Ying Z; Mach O; Sutter R; Wen N; Rodewald L; Li C; Wang J; Yuan H; Yin Z; Feng Z; Xu A; An Z
Lancet Reg Health West Pac; 2021 May; 10():100133. PubMed ID: 34327346
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analysis of the Instant and Persistent Inhibition Effects of Maternal Poliovirus Antibodies on the Immune Response in a Phase IV Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
Yin Q; Zheng Y; Ying Z; Li J; Jiang Y; Bao W; Dou Y; Pu Y; Lei J; Yang H; Jiang R; Deng Y; Zhao Z; Pu J; Yang J; Li Y; Xu M; Cai W; Che Y; Shi L
Vaccines (Basel); 2024 Feb; 12(2):. PubMed ID: 38400200
[TBL] [Abstract][Full Text] [Related]
13. Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes.
Daniell H; Rai V; Xiao Y
Plant Biotechnol J; 2019 Jul; 17(7):1357-1368. PubMed ID: 30575284
[TBL] [Abstract][Full Text] [Related]
14. Impact of enterovirus and other enteric pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infants.
Taniuchi M; Platts-Mills JA; Begum S; Uddin MJ; Sobuz SU; Liu J; Kirkpatrick BD; Colgate ER; Carmolli MP; Dickson DM; Nayak U; Haque R; Petri WA; Houpt ER
Vaccine; 2016 Jun; 34(27):3068-3075. PubMed ID: 27154394
[TBL] [Abstract][Full Text] [Related]
15. High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
Opmeer L; Gazzoli I; Ballmann M; Willemsen M; Voshol GP; Grudniewska-Lawton M; Havenga M; Yallop C; Hamidi A; Gillissen G; Bakker WAM
Vaccine; 2024 Apr; 42(9):2475-2484. PubMed ID: 38503660
[TBL] [Abstract][Full Text] [Related]
16. A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.
Kouiavskaia D; Chen Z; Dragunsky E; Mirochnitchenko O; Purcell R; Chumakov K
J Clin Virol; 2015 Apr; 65():32-7. PubMed ID: 25766984
[TBL] [Abstract][Full Text] [Related]
17. New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.
Knowlson S; Burlison J; Giles E; Fox H; Macadam AJ; Minor PD
PLoS Pathog; 2015 Dec; 11(12):e1005316. PubMed ID: 26720150
[TBL] [Abstract][Full Text] [Related]
18. Application of MPBT Assay for Multiplex Determination of Infectious Titers and for Selection of the Optimal Formulation for the Trivalent Novel Oral Poliovirus Vaccine.
Manukyan H; Lal M; Zhu C; Singh O; Lin TL; Tritama E; Chumakov K; Lee SM; Laassri M
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932253
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Immunogenicity and Safety of Three Enhanced Inactivated Poliovirus Vaccines from Different Manufacturers in Healthy Korean Infants: A Prospective Multicenter Study.
Kwak BO; Ma SH; Park SE; Shin SH; Choi KM; Lee TJ; Eun BW; Hong YJ; Kim DH
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32357552
[TBL] [Abstract][Full Text] [Related]
20. A Comparative Study of the Effects of Al(OH)
Heidary R; Nikbakht Brujeni G; Lotfi M; Hajizadeh A; Yousefi AR
Arch Razi Inst; 2023 Dec; 78(6):1779-1786. PubMed ID: 38828184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
